Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today the positive results of studies of the investigational medication guanfacine extended release (GXR, previously referred to as SPD503), a selective alpha-2A-adrenoceptor agonist. These data from two short-term phase III placebo-controlled studies and two long-term phase III open-label studies, presented at the 2007 American Psychiatric Association (APA) annual meeting, demonstrated that GXR significantly improved all core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6 to 17 years.

"Guanfacine extended release, the first selective alpha-2A-adrenoceptor agonist to be tested in well-controlled studies as a treatment for ADHD, holds potential based on the significant improvements in ADHD symptoms documented in four studies of this investigational drug," stated co-author Joseph Biederman, M.D., lead investigator, chief of clinical and research program in pediatric psychopharmacology at Massachusetts General Hospital and professor of psychiatry at Harvard Medical School. "Moreover, these data presented at this medical conference add evidence that GXR when dosed once daily may continue to control children's ADHD symptoms for up to 24 months."

GXR, a nonstimulant, is not a controlled substance and does not appear to have a mechanism for potential abuse or dependence. Shire submitted a New Drug Application (NDA) for GXR on August 24, 2006, which is currently under FDA review. The NDA provided data on GXR 1 mg to 4 mg taken once daily for the treatment of children and adolescents with ADHD.

GXR Yielded Significant Reductions in ADHD-RS-IV Scores in Two Short-Term Trials

Results from two short-term, double-blind, randomized phase III clinical trials presented at this medical conference, demonstrated that GXR significantly controlled all core symptoms of ADHD, including inattention, hyperac
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:10/6/2008)... Scientific Conference -, ORLANDO, Fla., Oct. 6 /...Microbia) today announced presentation of data fro...le that cyclic guanosine,monophosphate (cGMP) play...monstrate that cGMP inhibits intestinal pain in a ...esensitizes colonic afferent nerves in a,similar m...
(Date:10/6/2008)...urezol Dosed Prior to Surgery, TAMPA, Fla., Oct. ...vately held ophthalmic-focused biopharmaceutical c...dnate ophthalmic emulsion) 0.05% is now,commercial....S. Food and,Drug Administration in June 2008, is ...the treatment of inflammation and pain associated ...
(Date:10/6/2008)...evere patients achieved endoscopic,response and mo...t Week 10,in data from a 54-week open-label study ...ogy (ACG) Annual Scientific Meeting, ORLANDO, Fla... from a,large, prospective study investigating end... biologic compound. The data presented at the Amer...
(Date:10/6/2008).../ -- Dendreon Corporation (Nasdaq:,DNDN) will host...at 9:00 AM,ET (6:00 AM PT) to review the outcome o...y for Prostate AdenoCarcinoma Treatment, also know...ucel-T), the Company,s investigational,active cell...rostate,cancer., Those interested may access t...
Breaking Medicine Technology:Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Isis Receives 241 25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo 007 3193 1Isis Receives 241 25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo 007 3193 2Isis Receives 241 25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo 007 3193 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 1140 1Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 1140 2Two more American Cancer Society researchers win Nobel Prize 3191 1Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women 21 3187 1Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women 21 3187 2
...ay 29, 2007 - Pfizer said today that,results showi... as,melanoma, thyroid, liver, non-small cell lung ... (RCC) - a type of advanced kidney,cancer - will b...linical Oncology (ASCO) annual meeting in Chicago.... treatment, so,it,s critical that physicians have ...
...E)--May 29, 2007 - Introgen,Therapeutics, Inc. (NA...s will report updated Phase 2 clinical trial resul...at the upcoming,annual meetings of The American So...he American Society of Gene Therapy (ASGT) in,Seat...eline of,first-in-class cancer therapies generatin...
Other Medicine Technology:New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 2New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 3New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 4New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO 5Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 2Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings 3
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
...the advice about healthy diet, good sleep and exer...est beauty secret for a 'sparkling' complexion//. ...in this Rajasthan capital where more and more beau... 'bhasm' (ash) of stones like rubies, emeralds, pe...
...cale to measure the presence and severity of invol...n Parkinson's disease is being developed// and a c...y the Michael J. Fox Foundation for this purpose. ...sia Rating Scale will provide a critical research ...
... a dental health chief to give leadership and impl...l caries among children by 2026, says a British ex...lobal Child Dental Health Taskforce programme in I...mong children in the next 20 years, we need a good...
... reported that doctors from the Michigan State Uni...reatment plan, which allows a more effective// mea... people suffering from symptoms and conditions tha...mith, a physician and professor in MSU’s Departmen...
Other Medicine News:Health News:Astro Gem Therapy: The Latest Beauty Secret for Glowing Skin 2Health News:New Method For Measuring Dyskinesia In Parkinson's Being Developed 2Health News:New Method For Measuring Dyskinesia In Parkinson's Being Developed 3Health News:India needs dental health leadership, says expert 2Health News:India needs dental health leadership, says expert 3Health News:Revolutionary New Treatment Plan Developed For Treatment Of Unexplained Symptoms 2
...ilter units with hydrophobic PTFE membranes,Millex... are ideal for the sterilizing filtration of gases...lizing or clarifying organic solutions. Ready-to-u... with different outlet connections; other filter u...
...to Bottled Water, The Simplicity personal water sy... that currently use bottled water. In addition to ...ttled water, your laboratory applications may be a...tainers and cause water quality to degrade over ti...
Designed to meet the requirements of reagent grade water for routine analysis.
...in of Type I ultrapure water, , Ultrapure Water Qu...ed to provide the "final polish" to water which ha... or deionization. Super-Q Plus systems consistentl...pe I ASTM/CAP/NCCLS specifications.,The Super-Q Pl...
Medicine Products: